Equity Research Services-Medical Laboratories

Should You Buy Labcorp Holdings Inc. Stock in 2026?

By CirclFi Research Team · · 12/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Labcorp Holdings Inc. (LH) scores a robust 7.6/10 on our 32-signal Quality of Company framework. At the current market price of $281.48, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.

The short answer: 3 of 12 CirclFi valuation models project upside for Labcorp Holdings Inc. (LH) at $281.48 — the model consensus leans bearish, with a Quality Score of 7.6/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 9 of 12 models suggest overvaluation — majority bearish
  • Quality Score: 7.6/10 — Strong — above-average quality
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $80.36 – $657.17 (718% spread)

Bullish Models

3 / 12

Bearish Models

9 / 12

Quality Score

7.6 /10

Strong — above-average quality

Value Trap Risk

/100
Not scored

Not scored

Model Consensus

12 /13
Active Models

Avg. confidence: 51%

Investment Thesis

The Bull Case

Target: $657.17 (+133.5% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Labcorp Holdings Inc.'s score of 7.6/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
  • According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $657.17 (+133.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $80.36 (-71.5%)

  • According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $80.36 (-71.5%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +204.9% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.

Peer Benchmarking

CSTL Castle Biosciences,
9.2
VCYT Veracyte, Inc.
8.8
DGX Quest Diagnostics In
8.3
CDNA CareDx, Inc.
7.7
FLGT Fulgent Genetics, In
7.7

Valuation Divergence

Spread

718%

Fair Value Range

$80.36 – $657.17

A 718% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Markov DDM

$657.17 (+133.5%)

Most Bearish

EROIC

$80.36 (-71.5%)

Key Risk Factors

Model Disagreement

718% spread signals high variance in projections.

Bearish Consensus

9/12 models suggest overvaluation.

Macro/Sector Risk

Services-Medical Laboratories headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View LH Data Page →

The Bottom Line

Caution dominates our read on Labcorp Holdings Inc. at $281.48. 8 of 12 models see limited upside or outright downside, with the composite fair value at $231.15 (-17.9%). Quality at 7.6/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.

These are quantitative model outputs, not investment recommendations. Labcorp Holdings Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy LH stock right now?

Based on CirclFi's multi-model analysis, 3 of 12 models see upside for LH at $281.48. The models are divided, which means the investment case depends heavily on your assumptions about Labcorp Holdings Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Labcorp Holdings Inc.?

Key risks include: wide model disagreement (718% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-Medical Laboratories companies. Always diversify and consult a financial advisor.

How does LH compare to its competitors?

Among Services-Medical Laboratories peers, LH holds a Quality Score of 7.6/10. Comparable companies include CSTL (QOC 9.2), VCYT (QOC 8.8), DGX (QOC 8.3). The relative ranking helps investors identify whether LH offers better fundamental quality than alternatives in the same sector.

Is LH a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LH's Quality Score of 7.6/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy LH at?

CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $80.36 to $657.17. At $281.48, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for LH.

View LH Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →